The research, with the limits left in
Health Benefits of Mushroom Coffee: Evidence by Mushroom
By Brewlune · Published and research checked
The health benefits of mushroom coffee depend on the ingredient, preparation and dose. Small human trials suggest possible benefits for some outcomes, but findings are mixed and do not establish that a commercial coffee blend delivers the same effects. Brewlune publishes its recipe amounts so you can compare them with the research, not as proof of clinical effectiveness.
Brewlune sells the products discussed here. This is our editorial evidence review, not independent medical advice or a clinical trial of our products. No medical-review credential is claimed.
What does the evidence show for each mushroom?
These are selected studies for specific outcomes, not a claim that each mushroom has a proven benefit. A positive result in a particular population does not establish a general wellness effect. Scroll the table horizontally on smaller screens.
| Mushroom | Outcome studied / findings | Study type and sample | Evidence grade | Study preparation and daily dose | Brewlune per serving | Comparison limits |
|---|---|---|---|---|---|---|
| Lion's maneHericium erinaceus | Cognitive scores improved during treatment in a small trial of older adults with mild cognitive impairment; scores declined after stopping. This is not proof of everyday focus benefits in healthy coffee drinkers. | Mori et al., 2009, Phytotherapy Research. Double-blind, placebo-controlled human RCT; 30 randomized (15 per arm). Completion count is not specified in the abstract. | Limited | Four 250mg tablets, three times daily for 16 weeks: 3,000mg tablets/day, containing 96% dried mushroom powder (2,880mg powder). |
Published recipe amount—label verification pending. | Brewlune’s extract amount is lower by mass than the study’s daily powder amount. Extract and powder are not dose-equivalent; no validated conversion is available here. |
| Cordyceps militarisCordyceps militaris | Exercise tolerance was studied using a mixed-mushroom supplement. No significant treatment-by-time effects appeared after one week; a small three-week extension found a VO₂max signal. Benefits cannot be attributed to cordyceps alone. | Hirsch et al., 2017, Journal of Dietary Supplements; UNC Chapel Hill. Randomized, double-blind, placebo-controlled trial: 28 completed week one; 10 continued to three weeks. These are completion/extension counts, not a claim that all randomized participants completed. | Limited | 4,000mg/day of a cordyceps-containing mushroom blend for one week; ten volunteers continued for two additional weeks. Individual cordyceps dose not established by the blend total. |
Published recipe amount—label verification pending. | Do not compare Brewlune’s individual cordyceps amount with the whole 4,000mg study blend as though both were cordyceps. Composition and preparation differ. |
| ChagaInonotus obliquus | Isolated polysaccharides activated immune cells in laboratory experiments. This does not establish an immune-health benefit from drinking chaga or mushroom coffee. No qualifying randomized human benefits trial was identified in this review. | Wold et al., 2024, Communications Biology. Cell and animal experiments, including mouse and human macrophages. Human trial participant count: not applicable; human cells are not human trial participants. | Preliminary Animal/cell evidence only for the outcome described. | Isolated polysaccharides used in experimental systems; no established oral human study dose for this outcome. |
Published recipe amount—label verification pending. | There is no demonstrated human effective dose to match. Brewlune’s recipe amount cannot be translated into the laboratory concentrations or a proven benefit. |
| ReishiGanoderma lucidum in the cited trial | No improvement in blood glucose or other measured cardiovascular risk factors in adults with diabetes and metabolic syndrome. This is a negative finding, not a supported health benefit. | Klupp et al., 2016, Scientific Reports; Western Sydney University. Double-blind, placebo-controlled human RCT; 84 randomized across three arms. The abstract does not give a completion count; active arms were pooled. | Limited | Approximately 3,000mg/day for 16 weeks: a 10:1 Ganoderma extract plus spores, with or without 1,000mg Cordyceps sinensis extract. Active arms were pooled; this is not a pure reishi-only estimate. |
Published recipe amount—label verification pending. | Brewlune’s reishi amounts are lower by mass than the trial’s daily amount and are not demonstrated to be equivalent preparations. The trial did not establish a benefit at its own dose. |
- Strong
- Multiple consistent, high-quality human trials support the specific outcome.
- Moderate
- Human trials support the outcome, with meaningful limitations.
- Limited
- Human evidence is small, inconsistent, indirect, or methodologically weak.
- Preliminary
- Evidence is confined to animal, cell, or mechanistic research.
These are Brewlune editorial grades for the outcomes discussed, not formal Cochrane/GRADE assessments. “Limited” does not mean a benefit was demonstrated. No outcome in this table receives a Strong or Moderate rating.
The wider picture matters: a 2023 lion’s mane pilot in 41 healthy adults reported mixed findings at 1.8g/day; its stress result was a statistical trend, not a demonstrated reduction. Cochrane’s reishi review did not support treatment of cardiovascular risk factors. A 2026 reishi polysaccharide-peptide trial also found no significant between-group improvements in its measured inflammatory markers or lipid profile.
How Brewlune’s formulas compare with the research
For a coffee with all four published mushroom amounts, consider Brewlune Dawn Patrol or Point Break. Choose Glassy for matcha, or Last Light for cacao. These are ingredient and beverage choices, not a ranking of clinical effectiveness. Our product images show the same mushroom amounts as the recipe data, but current physical-package verification is pending; the figures are not finished-product assays. Our specifications describe mushroom extracts; extract ratios have not been verified here. Serving weights below are published recipe specifications.
Brewlune Dawn Patrol
Instant mushroom coffee · 3.5g serving
- Lion's mane: 500mg
- Cordyceps militaris: 400mg
- Chaga: 300mg
- Reishi: 300mg
48mg caffeine, recipe estimate.
Brewlune Point Break
Full-cup mushroom coffee · 4g serving
- Lion's mane: 500mg
- Cordyceps militaris: 400mg
- Chaga: 300mg
- Reishi: 300mg
95mg caffeine, recipe estimate.
Brewlune Glassy
Ceremonial-grade matcha · 2.3g serving
- Lion's mane: 500mg
- Cordyceps militaris: 400mg
- Chaga: Not included
- Reishi: Not included
40mg caffeine, recipe estimate.
Brewlune Last Light
Evening cacao · 7.4g serving
- Lion's mane: Not included
- Cordyceps militaris: Not included
- Chaga: 300mg
- Reishi: 600mg
No added caffeine; estimated 2–10mg naturally from cacao. Not caffeine-free.
Compare published mushroom doses, review our testing status, or read whether mushroom coffee is worth it. No public finished-product Brewlune batch COA is available in this review.
What this table cannot establish—and safety context
Species, extraction method, active constituents, population and duration all affect whether research applies. A mushroom blend study cannot isolate one ingredient’s effect. Do not multiply servings to imitate a research dose: matching mass would not establish equivalent effects or safety.
A published chaga case report describes oxalate-related kidney injury after prolonged consumption of chaga powder. A case report cannot estimate risk from Brewlune or establish a safe dose. See our chaga field note for context. If you have kidney disease, take medicines, are pregnant or breastfeeding, discuss mushroom supplements with your clinician before use. Do not use this page to replace treatment.
Questions about mushroom coffee benefits
+Are mushroom coffee benefits clinically proven?
The ingredient studies reviewed here do not establish clinical benefits for Brewlune’s finished coffee, matcha or cacao blends. Small trials, different preparations and mixed formulations limit what can be concluded.
+Does a printed mushroom dose mean it matches a clinical trial?
No. Compare the species, powder or extract, preparation, daily amount, duration and study population. A printed recipe amount is not a finished-product assay or a clinically effective dose.
+Should I drink more servings to match a study dose?
No. These comparisons are not dosing instructions. Extra servings also change caffeine and other ingredient intake, and matching ingredient mass would not establish equivalent effects or safety.
+Which Brewlune blend contains these mushrooms?
Dawn Patrol and Point Break contain all four. Glassy contains lion’s mane and cordyceps; Last Light contains reishi and chaga. Choose by ingredients, beverage base and caffeine preference, not an unproven therapeutic ranking.
Sources and how we selected them
We searched PubMed-indexed studies and Cochrane reviews using common and scientific mushroom names with human, randomized trial, cognition, exercise, immune and cardiovascular terms on November 2, 2026. This is a focused editorial review, not an exhaustive systematic review. We prioritized controlled human studies with identifiable doses and populations; where no qualifying human benefits RCT was identified, we labeled preclinical work explicitly. We considered negative findings and review-level evidence rather than selecting only favorable results.
Mori was selected for a clearly described 16-week cognitive trial, with the healthy-adult pilot included to show limits of generalization. Hirsch directly addresses exercise but cannot isolate cordyceps. Wold illustrates the preclinical nature of the chaga outcome. Klupp provides a substantial negative reishi trial, contextualized by Cochrane and a newer trial. These are research examples, not endorsements of Brewlune.
- Mori et al., 2009 — Phytotherapy Research
- Docherty et al., 2023 — Nutrients
- Hirsch et al., 2017 — Journal of Dietary Supplements
- Wold et al., 2024 — Communications Biology
- Klupp et al., 2016 — Scientific Reports
- Cochrane, 2015 — Reishi and cardiovascular risk factors
- Abshori et al., 2026 — Current Drug Discovery Technologies
- Kikuchi et al., 2014 — Clinical Nephrology (case report)